Please login to the form below

Not currently logged in
Email:
Password:

AZ

This page shows the latest AZ news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK. Latest salvo in combination trials competition. ... AZ has previously said it will file for approval in Japan and China before the end of this year, and in the US and Europe in early 2019.

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    AZ nabs US approval for new leukaemia drug Lumoxiti. Adds to firm's growing oncology franchise. ... Lumoxiti (moxetumomab pasudotox-tdfk) is the first new treatment for this type of leukaemia in 20 years, according to AZ.

  • FDA rejects GSK’s Nucala for COPD FDA rejects GSK’s Nucala for COPD

    Another potentially strong challenge could come from AZ and Amgen’s tezepelumab, which has just been awarded a breakthrough designation from the FDA for severe asthma. ... In May, AZ’s Fasenra failed a phase III trial in this indication as it was

  • FDA rejects GSK’s Nucala for COPD FDA rejects GSK’s Nucala for COPD

    Another potentially strong challenge could come from AZ and Amgen’s tezepelumab, which has just been awarded a breakthrough designation from the FDA for severe asthma. ... In May, AZ’s Fasenra failed a phase III trial in this indication as it was

  • AZ, Amgen’s first-in-class asthma drug gets breakthrough status AZ, Amgen’s first-in-class asthma drug gets breakthrough status

    AZ, Amgen’ s first-in-class asthma drug gets breakthrough status. The IL-5 inhibitor is already approved for severe asthma in the EU. ... AstraZeneca and partner Amgen have picked up a breakthrough designation from the FDA for tezepelumab, a drug that

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    alongside AZ’s EGFR inhibitor Iressa (gefitinib), as well as gastric cancer.

More from news
Approximately 59 fully matching, plus 822 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    And AZ’s Imfinzi (durvalumab) meanwhile has shown its worth as a maintenance therapy to stop recurrence of earlier-stage, locally-advanced NSCLC. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug

  • 30 Women Leaders in UK Healthcare

    5. Lisa Anson, Redx CEO, former President of AZ UK. Lisa Anson has been one of the UK pharma industry’s most high-profile women leaders since being appointed President of

  • The good, the bad and the ugly The good, the bad and the ugly

    GSK, AZ and Chiesi are each playing in this new market.

  • The bulk of pharma digital spend fails to alter industry’s greenhorn status The bulk of pharma digital spend fails to alter industry’s greenhorn status

    Pfizer, AstraZeneca and Merck fare well on the Cx scores, largely due to the relevance of content provided to HCPs on the go, while Pfizer, Amgen and AZ outscored others on

  • Digital disruption Digital disruption

    AZ and Microsoft. One more of the IT companies joining force with a pharma partner is Microsoft. ... The work began when senior Microsoft scientist Jasmin Fisher was invited to speak at AZ’s first Cambridge Cancer Science Symposium in 2014.

More from intelligence
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    Congenica poaches AZ’s business performance director. Currently director of business performance at AstraZeneca, Wendy Britten (pictured) has decided to join Cambridge, UK-based Cogenica, a clinical genomics interpretation software provider.

  • AZ and Medimmune bolsters immuno-oncology leadership AZ and Medimmune bolsters immuno-oncology leadership

    AZ and Medimmune bolsters immuno-oncology leadership. Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. ... Soria also taking up a leadership role within AZ ’s global biologics research and development arm MedImmune, will lead a team

  • GSK appoints president of global pharmaceuticals GSK appoints president of global pharmaceuticals

    Miels joins the UK-headquartered firm from AstraZeneca, where he is currently executive vice president of AZ's European business. ... He moved to AZ from Roche in 2014, having been regional vice president of its Asia-Pacific pharmaceutical operations,

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    AstraZeneca appoints head of oncology. Dr Jamie Freedman joins from AZ subsidiary MedImmune.

  • Former AZ oncology head joins Innate Pharma Former AZ oncology head joins Innate Pharma

    chairman of the executive board at the French biotech " /. chairman of the executive board at the French biotech " /. Former AZ oncology head joins Innate Pharma. Dr Mondher Mahjoubi becomes chairman of

More from appointments
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics